| 0.6075 0.026 (4.53%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.84 | 1-year : | 1.09 |
| Resists | First : | 0.72 | Second : | 0.93 |
| Pivot price | 0.51  |
|||
| Supports | First : | 0.37 | Second : | 0.31 |
| MAs | MA(5) : | 0.57  |
MA(20) : | 0.48 |
| MA(100) : | 0.47 |
MA(250) : | 0.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.9 |
D(3) : | 32.2 |
| RSI | RSI(14): 63.3 |
|||
| 52-week | High : | 2.4 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HBIO ] has closed below upper band by 22.4%. Bollinger Bands are 166% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.64 | 0.64 - 0.64 |
| Low: | 0.54 - 0.54 | 0.54 - 0.54 |
| Close: | 0.6 - 0.61 | 0.61 - 0.61 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Sun, 09 Nov 2025
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Bounce 29% But Its Business Still Trails The Industry - 富途牛牛
Sun, 09 Nov 2025
Analysts Have Been Trimming Their Harvard Bioscience, Inc. (NASDAQ:HBIO) Price Target After Its Latest Report - Yahoo Finance
Sat, 08 Nov 2025
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 07 Nov 2025
Is It Time To Consider Buying Harvard Bioscience, Inc. (NASDAQ:HBIO)? - Yahoo Finance
Thu, 06 Nov 2025
Harvard Bioscience: Q3 Earnings Snapshot - Norwalk Hour
Thu, 06 Nov 2025
Harvard Bioscience: Q3 Earnings Snapshot - CTPost
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 45 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 54.8 (%) |
| Shares Short | 580 (K) |
| Shares Short P.Month | 657 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -64.7 % |
| Operating Margin | -3.1 % |
| Return on Assets (ttm) | -2 % |
| Return on Equity (ttm) | -138.4 % |
| Qtrly Rev. Growth | -11.5 % |
| Gross Profit (p.s.) | 1.13 |
| Sales Per Share | 1.99 |
| EBITDA (p.s.) | 0.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 10 (M) |
| PE Ratio | -0.48 |
| PEG Ratio | 0 |
| Price to Book value | 1.73 |
| Price to Sales | 0.3 |
| Price to Cash Flow | 4.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|